Last reviewed · How we verify
Enaroy — Competitive Intelligence Brief
marketed
Egl nine homolog 1
Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Enaroy (ENARODUSTAT) — Japan Tabacco.
Comparator set (4 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Enaroy TARGET | ENARODUSTAT | Japan Tabacco | marketed | Egl nine homolog 1 | ||
| Jesduvroq | DAPRODUSTAT | GSK | marketed | Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor [EPC] | Egl nine homolog 1 | 2023-01-01 |
| Allomaleic Acid | FUMARIC ACID | marketed | Vitamin C [EPC] | Egl nine homolog 1 | ||
| Musredo | MOLIDUSTAT | BAYER YAKUHIN, Ltd | marketed | Egl nine homolog 1 | ||
| Butanedioic Acid | SUCCINIC ACID | marketed | Vitamin C [EPC] | Egl nine homolog 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Enaroy — Competitive Intelligence Brief. https://druglandscape.com/ci/enarodustat. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab